Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European Phase III Diamyd Trial
NCT00723411Phase 3Terminated
- Sponsor
- Diamyd Medical
- Start
- Jul 2008
- Primary completion
- May 2011
- Modality
- Recombinant Proteins and Enzymes, Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of Diamyd in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Diamyd Medical. Primary endpoint: Meal stimulated C-peptide (area under the curve) at 15 months. Started Jul 2008; status: terminated.
02
Drugs
Diamyd
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00723411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00723411.